Back to top
more

Diversified Healthcare Trust (DHC)

(Delayed Data from NSDQ)

$3.43 USD

3.43
768,500

+0.02 (0.59%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $3.44 +0.01 (0.29%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 246)

Industry: REIT and Equity Trust - Other

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Diversified Healthcare (DHC) Loses -18.22% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for Diversified Healthcare (DHC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

New Strong Buy Stocks for May 16th

by Zacks Equity Research

KMT, IDCC, SAND, DHC and ASTE have been added to the Zacks Rank #1 (Strong Buy) List on May 16, 2023.

Zacks Equity Research

Best Growth Stocks to Buy for May 16th

by Zacks Equity Research

DHC, PERI and EZPW made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 16, 2023.

Zacks Equity Research

Best Value Stocks to Buy for May 16th

by Zacks Equity Research

DHC, AGCO and PERI made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 16, 2023.

Zacks Equity Research

DHC or OFC: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DHC vs. OFC: Which Stock Is the Better Value Option?

Zacks Equity Research

Down -18.08% in 4 Weeks, Here's Why Diversified Healthcare (DHC) Looks Ripe for a Turnaround

by Zacks Equity Research

Diversified Healthcare (DHC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Diversified Healthcare (DHC) Matches Q1 FFO Estimates

by Zacks Equity Research

Diversified Healthcare (DHC) delivered FFO and revenue surprises of 0% and 0.79%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Postal Realty Trust (PSTL) Surpasses Q1 FFO and Revenue Estimates

by Zacks Equity Research

Postal Realty Trust (PSTL) delivered FFO and revenue surprises of 8% and 0.95%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Diversified Healthcare (DHC) Tops Q4 FFO Estimates

by Zacks Equity Research

Diversified Healthcare (DHC) delivered FFO and revenue surprises of 400% and 0.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Modiv Inc. (MDV) Surpasses Q4 FFO and Revenue Estimates

by Zacks Equity Research

Modiv Inc. (MDV) delivered FFO and revenue surprises of 106.06% and 30.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Sell Stocks for December 30th

by Zacks Equity Research

DHC, PLMR and WEBR have been added to the Zacks Rank #5 (Strong Sell) List on December 30, 2022.

Zacks Equity Research

SBA Communications (SBAC) Surpasses Q3 FFO and Revenue Estimates

by Zacks Equity Research

SBA Communications (SBAC) delivered FFO and revenue surprises of 1.97% and 3.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Piedmont Office (PDM) Q2 FFO Match Estimates

by Zacks Equity Research

Piedmont Office (PDM) delivered FFO and revenue surprises of 0% and 0.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Crown Castle (CCI) Q2 FFO and Revenues Surpass Estimates

by Zacks Equity Research

Crown Castle (CCI) delivered FFO and revenue surprises of 0.56% and 1.22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Diversified Healthcare (DHC) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Diversified Healthcare (DHC) delivered FFO and revenue surprises of -350% and 2.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Diversified Healthcare (DHC) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Diversified Healthcare (DHC) delivered FFO and revenue surprises of -275% and 0.75%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Capstar Financial (CSTR) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Capstar Financial (CSTR) delivered earnings and revenue surprises of 9.80% and 1.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Diversified Healthcare (DHC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Diversified Healthcare (DHC) delivered FFO and revenue surprises of -233.33% and -1.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What's in the Cards for Ventas (VTR) This Earnings Season?

by Zacks Equity Research

While Ventas (VTR) is well poised to bank on the senior housing industry's recovery that is likely to have aided it in Q2, disposition of assets and higher expenses might have been deterrents.

Zacks Equity Research

Diversified Healthcare (DHC) Tops Q2 FFO Estimates

by Zacks Equity Research

Diversified Healthcare (DHC) delivered FFO and revenue surprises of 150.00% and -6.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is Diversified Healthcare (DHC) a Great Stock for Value Investors?

by Zacks Equity Research

Is Diversified Healthcare (DHC) a great pick from the value investor's perspective right now? Read on to know more.

Zacks Equity Research

Diversified Healthcare (DHC) Misses Q1 FFO and Revenue Estimates

by Zacks Equity Research

Diversified Healthcare (DHC) delivered FFO and revenue surprises of -33.33% and -0.27%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ventas (VTR) to Post Q1 Earnings: What's in the Offing?

by Zacks Equity Research

While the gradual rebound in clinical activity is expected to have supported Ventas' (VTR) office segment performance, the pandemic-led concerns continued to be setbacks for its seniors housing business.

Zacks Equity Research

Is Recovery in the Cards for Welltower (WELL) in Q1 Earnings?

by Zacks Equity Research

Despite increased coverage of vaccine administration among senior housing residents, Welltower (WELL) witnesses a significant occupancy decline at its senior housing operating portfolio in Q1.

Zacks Equity Research

Life-Science Assets to Aid Ventas (VTR) Amid Pandemic Woes

by Zacks Equity Research

Amid the COVID-19 outbreak, which is taking a toll on Ventas' (VTR) senior housing operations, the company is attuning its portfolio with higher exposure to resilient office segment assets.